Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

ClinicalTrials.gov ID: NCT00061776

Public ClinicalTrials.gov record NCT00061776. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

Study identification

NCT ID
NCT00061776
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
NeurogesX
Industry
Enrollment
300 participants

Conditions and interventions

Interventions

  • Capsaicin Dermal Patch Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Not listed
Last update posted
Mar 5, 2008

United States locations

U.S. sites
28
U.S. states
16
U.S. cities
28
Facility City State ZIP Site status
NeurogesX Investigational Site Huntsville Alabama 35801
NeurogesX Investigational Site Phoenix Arizona 85023
NeurogesX Investigational Site Scottsdale Arizona
NeurogesX Investigational Site Tucson Arizona 85724
NeurogesX Investigational Site Little Rock Arkansas 72205
NeurogesX Investigational Site La Jolla California 92037
NeurogesX Investigational Site San Francisco California 94117
NeurogesX Investigational Site Denver Colorado 80218
NeurogesX Investigational Site Melbourne Florida 32935
NeurogesX Investigational Site Naples Florida 34102
NeurogesX Investigational Site Ocala Florida 34471
NeurogesX Investigational Site Palm Beach Garden Florida 33410
NeurogesX Investigational Site Plantation Florida 33324
NeurogesX Investigational Site Sarasota Florida 34232
NeurogesX Investigational Site St. Petersburg Florida 33702
NeurogesX Investigational Site Boston Massachusetts 02115
NeurogesX Investigational Site Kansas City Missouri 64132
NeurogesX Investigational Site Las Vegas Nevada 89102
NeurogesX Investigational Site Morristown New Jersey 07960
NeurogesX Investigational Site Albany New York 12205
NeurogesX Investigational Site Rochester New York 14642
NeurogesX Investigational Site Eugene Oregon 97401
NeurogesX Investigational Site Memphis Tennessee 93104
NeurogesX Investigational Site Austin Texas 78758
NeurogesX Investigational Site Dallas Texas 75234
NeurogesX Investigational Site San Antonio Texas 78229
NeurogesX Investigational Site Salt Lake City Utah 84107
NeurogesX Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00061776, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2008 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00061776 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →